Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ZIOPHARM Oncology stock

Learn how to easily invest in ZIOPHARM Oncology stock.

ZIOPHARM Oncology Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ZIOPHARM Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZIOP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ZIOPHARM Oncology stock price (NASDAQ: ZIOP)

Use our graph to track the performance of ZIOP stocks over time.

ZIOPHARM Oncology shares at a glance

Information last updated 2022-01-17.
Latest market close$0.82
52-week range$0.85 - $5.95
50-day moving average $1.27
200-day moving average $2.13
Wall St. target price$3.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.42

Buy ZIOPHARM Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ZIOPHARM Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ZIOPHARM Oncology price performance over time

Historical closes compared with the close of $0.817 from 2022-01-21

1 week (2022-01-13) -7.47%
1 month (2021-12-19) N/A
3 months (2021-10-22) -48.29%
6 months (2021-07-23) -63.53%
1 year (2021-01-22) -77.49%
2 years (2020-01-23) -81.80%
3 years (2019-01-23) 2.02
5 years (2017-01-23) 5.67

ZIOPHARM Oncology financials

Revenue TTM $398,000
Gross profit TTM $-52,696,000
Return on assets TTM -39.32%
Return on equity TTM -84.01%
Profit margin 0%
Book value $0.32
Market capitalisation $204.5 million

TTM: trailing 12 months

ZIOPHARM Oncology share dividends

We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.

Have ZIOPHARM Oncology's shares ever split?

ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.

ZIOPHARM Oncology share price volatility

Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $0.851 up to $5.95. A popular way to gauge a stock's volatility is its "beta".

ZIOP.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 1.6868. This would suggest that ZIOPHARM Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ZIOPHARM Oncology overview

ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.

Frequently asked questions

What percentage of ZIOPHARM Oncology is owned by insiders or institutions?
Currently 9.927% of ZIOPHARM Oncology shares are held by insiders and 56.265% by institutions.
How many people work for ZIOPHARM Oncology?
Latest data suggests 103 work at ZIOPHARM Oncology.
When does the fiscal year end for ZIOPHARM Oncology?
ZIOPHARM Oncology's fiscal year ends in December.
Where is ZIOPHARM Oncology based?
ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129
What is ZIOPHARM Oncology's ISIN number?
ZIOPHARM Oncology's international securities identification number is: US98973P1012
What is ZIOPHARM Oncology's CUSIP number?
ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site